Difference between revisions of "Crizanlizumab (Adakveo)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 15: | Line 15: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Anti-P-selectin antibodies]] | [[Category:Anti-P-selectin antibodies]] | ||
Revision as of 19:40, 27 February 2020
Mechanism of action
Definition from the NCI Drug Dictionary: A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells.
Diseases for which it is used
History of changes in FDA indication
- 11/15/2019: Approved to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
Also known as
- Code name: SEG101
- Generic name: crizanlizumab-tmca
- Brand name: Adakveo